![](https://nthumb.tpgimages.com/mid2_com_img/1339/29176/TOP27276790.jpg)
MODEL RELEASED. Packaging for a pre-filled pen for injecting the migraine drug fremanezumab, marketed as Ajovy. This is a preventative treatment that is injected once a month. It is a humanised monoclonal antibody that blocks the calcitonin gene-related peptide receptor (CGRPR). Calcitonin gene-related peptide (CGRP) is a small protein that is released as a result of brain changes during migraine. Binding of CGRP to its receptor causes vasodilation (the widening of blood vessels) in the brain, which leads to headache. Fremanezumab was approved for treatment in the UK in 2020.
px | px | dpi | = | cm | x | cm | = | MB |
Details
Creative#:
TOP27276790
Source:
達志影像
Authorization Type:
RM
Release Information:
須由TPG 完整授權
Model Release:
Yes
Property Release:
No
Right to Privacy:
No
Same folder images: